(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
23 April 2009 (23.04.2009)

PCT

(10) International Publication Number
WO 2009/052184 A3

(51) International Patent Classification:
C07K 14/71 (2006.01) *A61K 38/17* (2006.01)

(21) International Application Number:
PCT/US2008/079998

(22) International Filing Date: 15 October 2008 (15.10.2008)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/980,424 16 October 2007 (16.10.2007) US
61/043,308 8 April 2008 (08.04.2008) US

(71) Applicant *(for all designated States except US)*: **RECEPTOR BIOLOGIX, INC.** [US/US]; 3350 W. Bayshore Road, Suite 150, Palo Alto, CA 94303 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **SHEPARD, H., Michael** [US/US]; 75 Magellan Drive, San Francisco, CA 94116 (US). **JIN, Pei** [US/US]; 320 Curtner Avenue, Unit D, Palo Alto, CA 94306 (US).

(74) Agents: **SHIEH-NEWTON, Terri** et al.; Morrison & Foerster LLP, 755 Page Mill Road, Palo Alto, CA 94304-1018 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

(88) Date of publication of the international search report:
11 June 2009

(54) Title: COMPOSITIONS COMPRISING OPTIMIZED HER1 AND HER3 MULTIMERS AND METHODS OF USE THEREOF

Figure 4 Optimization of Her1 and Her3 ECD AA

	TGFα	HFD100	HFD120	Fold Improvement	CC
	KD (nM)	38.1	1.7	> 22.6	
DD	On (T1/2 min)	5.7	3.4	1.7	
EE	Off (T1/2 min)	48.8	86.0	1.8	
	Bmax (CPM)	375	3810	10.2	

NRG1β	HFD300.1	HFD320.1	Fold Improvement
KD (nM)	12.1	1.4	8.7
On (T1/2 min)	3.1	1.0	3.2
Off (T1/2 min)	3.3	4.7	1.4
Bmax (CPM)	1880	7490	4.0

BB On/Off half-time and Bmax values were measured with 10 nM of ^{125}I-ligands



(57) Abstract: The invention provides for compositions comprising engineered Her3 multimers with improved binding affinity. Such multimers include, but are not limited to, Herl/Her 3 heterodimers in which the Her3 ligand binding domain has been optimized to increase binding to Her3. The composition also can include mixtures of Her 1 homodimers, Her 3 homodimers, and Her 1/Her 3 heterodimers.

WO 2009/052184 A3